-  INCLUSION CRITERIA:

          -  Histologically or cytologically confirmed diagnosis of a solid tumor malignancy for

        which no curative therapy exists as confirmed by the NCI Laboratory of Pathology.

          -  For expansion cohort: histologically or cytologically confirmed diagnosis of non-
             neuroendocrine pancreatic cancer. Participants with mixed acinar-neuroendocrine
             histology are permitted.

          -  Participants in the Biopsy Arm of the expansion cohort must have disease amenable to
             safe biopsy and willingness to undergo the procedure.

          -  Participants must have received at least one prior systemic treatment for advanced
             disease. Participants must be more than 14 days removed from most recent standard of
             care or experimental drug treatment for their tumor

          -  Participants in the dose escalation cohort must have evaluable disease, either by
             clinical exam, biochemical markers (including but not limited to CA 19-9 serum tumor
             marker for pancreatobiliary cancer participants, or other appropriate tumor marker in
             other tumor types), and/or radiographic studies.

          -  Participants in the expansion cohort must have measurable disease, per RECIST 1.1.

          -  Age >=18 years. Because no dosing or adverse event data are currently available on the
             use of ProAgio in participants <18 years of age, children are excluded from this
             study.

          -  ECOG performance status <=2 (Karnofsky >= 60%).

          -  Participants must have adequate organ and marrow function as defined below:

               -  absolute neutrophil count >=1,000/mcL

               -  hemoglobin >=9 g/ dL

               -  platelets >=75,000/mcL

               -  AST(SGOT)/ALT(SGPT) <= 2.5 x ULN. AST and ALT (up to 5x ULN is permitted for
                  participants with liver metastases)

               -  Total bilirubin <=1.5 X institutional ULN

               -  creatinine within normal institutional limits

        OR

          -  creatinine clearance >=60 mL/min/1.73 m^2 for participants with creatinine levels
             above institutional normal

          -  Serum albumin > 2.5 mg/dL without intravenous supplementation

             -Participants must have:

          -  Resting systolic blood pressure < 145 and diastolic blood pressure < 90.

          -  Baseline QTcF interval of <= 470 ms

          -  Baseline resting heart rate > 45 beats per minute and <100 beats per minute

               -  The effects of ProAgio on the developing human fetus are unknown. For this
                  reason, women of child-bearing potential and men must agree to use adequate
                  contraception (hormonal or barrier method of birth control; abstinence) prior to
                  study entry, for the duration of study participation and for the 3 months
                  following the last dosing of study drug. Should a woman become pregnant or
                  suspect she is pregnant while she or her partner is participating in this study,
                  she should inform her treating physician immediately.

               -  Ability of subject to understand and the willingness to sign a written informed
                  consent document

        EXCLUSION CRITERIA:

          -  Diagnosis of primary malignant CNS tumor

          -  Participants who are receiving any other investigational agents.

          -  Evidence of significant, uncontrolled concomitant diseases which could affect

        compliance with the protocol or interpretation of results, including but not limited to
        significant pulmonary disease other than that related to the primary cancer, uncontrolled
        diabetes mellitus, unstable angina, significant cardiovascular disease (such as New York
        Heart Association Class III or IV cardiac disease) and/or psychiatric illness/social
        situations within 12 weeks that would limit compliance with study requirements.

          -  Participants with known diagnosis of a chronic neurologic disorders (such as multiple
             sclerosis, Huntington s disease, Parkinson s disease, or uncontrolled epilepsy) which
             causes motor disturbance, visual disturbance or seizure and could confound assessment
             of neurologic toxicity caused by the study drug.

          -  Pregnant or nursing women are excluded from this study because ProAgio is an agent
             with the potential for teratogenic or abortifacient effects. Because there is an
             unknown but potential risk for adverse events in nursing infants secondary to
             treatment of the mother with ProAgio, breastfeeding should be discontinued if the
             mother is treated with ProAgio.

          -  Participants with leptominengeal disease or with CNS metastases that are untreated,
             have required steroid treatment within the last 4 weeks, or anti-convulsant therapy in
             the last 14 days. For dose escalation cohort only: Participants with any known CNS
             metastases are excluded. Those with symptoms suggestive of possible CNS metastases
             (such as new headaches) must undergo brain MRI as part of screening.

          -  Participants who have undergone a recent minor surgical procedure (within <=14 days)
             such as biliary stenting or major surgical procedure (within <= 28 days) are excluded.

          -  Participants who have undergone recent (within <=14 days) radiation therapy are
             excluded.

          -  Participants with uncontrolled bleeding episodes <=28 days prior to enrollment are
             excluded.

          -  Participants with active or uncontrolled infections are excluded.

          -  Participants with HIV and detectable viral load are excluded. Patents on appropriate
             highly active anti-retroviral therapy with undetectable viral load are eligible.

          -  Participants with a history of Hepatitis B or C are excluded unless there is
             documented evidence of effective treatment and/or cure with undetectable viral load.

          -  Participants with recent (within <= 28 days) thromboembolic disease including but not
             limited to acute coronary syndrome, stroke, or transient ischemic attack, recent deep
             vein thrombosis or pulmonary embolism are excluded.

          -  Participants with thromboembolic disease including but not limited to acute coronary
             syndrome, stroke, or transient ischemic attack, recent deep vein thrombosis or
             pulmonary embolism who have continued symptoms, or who are not on stable doses of
             appropriate

        antiplatelet/anticoagulant regimens are excluded.